Ikaros family zinc finger 1 (IKZF1) mRNA (IKZF1 mRNA)

Ikaros family zinc finger 1 (IKZF1) mRNA encodes the Ikaros protein, a critical zinc-finger transcription factor that serves as a master regulator of hematopoietic stem cell differentiation and lymphoid development [1, 5]. It is essential for the specification and maturation of B cells, T cells, and natural killer cells by modulating gene expression through chromatin remodeling and direct DNA binding [1]. In clinical oncology, IKZF1 is a major focal point because its dysregulation, particularly through genomic deletions or loss-of-function mutations, is a hallmark of high-risk B-cell precursor acute lymphoblastic leukemia (B-ALL) and is associated with poor therapeutic outcomes [4]. While the mRNA itself is a potential target for experimental RNA-interference technologies, the protein product is the primary target of immunomodulatory imide drugs (IMiDs) such as lenalidomide and pomalidomide [2, 3]. These drugs function as molecular glues that facilitate the interaction between Ikaros and the cereblon (CRBN) E3 ubiquitin ligase, leading to the rapid ubiquitination and proteasomal degradation of the protein, which triggers apoptosis in malignant cells like those found in multiple myeloma [2, 3]. Consequently, monitoring IKZF1 mRNA levels and genetic status is vital for assessing drug sensitivity and disease progression in hematologic malignancies [4].

Other names

IK1 mRNAZNFN1A1 mRNALYF1 mRNAIkaros mRNAhIkaros mRNA

Immunomodulatory imide drugs (IMiDs) function as molecular glues that bind to the cereblon (CRBN) E3 ubiquitin ligase complex, inducing the recruitment and subsequent proteasomal degradation of the Ikaros (IKZF1) protein product translated from the mRNA. Experimental therapeutic approaches such as siRNA or antisense oligonucleotides (ASOs) target the IKZF1 mRNA transcript directly to induce its degradation or inhibit translation, thereby reducing Ikaros protein levels.